Anticoagulation Strategies in Patients With Cancer : JACC Review Topic of the Week
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
---|---|
Enthalten in: |
Journal of the American College of Cardiology - 73(2019), 11 vom: 26. März, Seite 1336-1349 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mosarla, Ramya C [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anticoagulants |
---|
Anmerkungen: |
Date Completed 27.02.2020 Date Revised 19.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1016/j.jacc.2019.01.017 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM295208260 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM295208260 | ||
003 | DE-627 | ||
005 | 20231225083145.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jacc.2019.01.017 |2 doi | |
028 | 5 | 2 | |a pubmed24n0984.xml |
035 | |a (DE-627)NLM295208260 | ||
035 | |a (NLM)30898209 | ||
035 | |a (PII)S0735-1097(19)30274-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mosarla, Ramya C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anticoagulation Strategies in Patients With Cancer |b JACC Review Topic of the Week |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.02.2020 | ||
500 | |a Date Revised 19.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
520 | |a Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Review | |
650 | 4 | |a anticoagulation | |
650 | 4 | |a atrial fibrillation | |
650 | 4 | |a bleeding | |
650 | 4 | |a cancer | |
650 | 4 | |a cardio-oncology | |
650 | 4 | |a venous thromboembolism | |
650 | 7 | |a Anticoagulants |2 NLM | |
700 | 1 | |a Vaduganathan, Muthiah |e verfasserin |4 aut | |
700 | 1 | |a Qamar, Arman |e verfasserin |4 aut | |
700 | 1 | |a Moslehi, Javid |e verfasserin |4 aut | |
700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
700 | 1 | |a Giugliano, Robert P |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 73(2019), 11 vom: 26. März, Seite 1336-1349 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
773 | 1 | 8 | |g volume:73 |g year:2019 |g number:11 |g day:26 |g month:03 |g pages:1336-1349 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2019.01.017 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 73 |j 2019 |e 11 |b 26 |c 03 |h 1336-1349 |